TR201112295Y - transkripsiyon infidelitesi, tespit edilmesi ve kullanımları - Google Patents
transkripsiyon infidelitesi, tespit edilmesi ve kullanımları Download PDFInfo
- Publication number
- TR201112295Y TR201112295Y TR2011/12295U TR201112295U TR201112295Y TR 201112295 Y TR201112295 Y TR 201112295Y TR 2011/12295 U TR2011/12295 U TR 2011/12295U TR 201112295 U TR201112295 U TR 201112295U TR 201112295 Y TR201112295 Y TR 201112295Y
- Authority
- TR
- Turkey
- Prior art keywords
- infidelity
- protein
- sequence
- transcriptional
- transcription
- Prior art date
Links
- 238000013518 transcription Methods 0.000 title claims abstract description 168
- 230000035897 transcription Effects 0.000 title claims abstract description 168
- 238000001514 detection method Methods 0.000 title description 24
- 238000000034 method Methods 0.000 claims abstract description 143
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 238000012216 screening Methods 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 274
- 102000004169 proteins and genes Human genes 0.000 claims description 168
- 230000002103 transcriptional effect Effects 0.000 claims description 143
- 206010028980 Neoplasm Diseases 0.000 claims description 84
- 201000011510 cancer Diseases 0.000 claims description 76
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 61
- 238000006467 substitution reaction Methods 0.000 claims description 58
- 108020004414 DNA Proteins 0.000 claims description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 27
- 238000003780 insertion Methods 0.000 claims description 26
- 230000037431 insertion Effects 0.000 claims description 26
- 230000008859 change Effects 0.000 claims description 22
- 238000012217 deletion Methods 0.000 claims description 20
- 230000037430 deletion Effects 0.000 claims description 20
- 108010052285 Membrane Proteins Proteins 0.000 claims description 12
- 102000018697 Membrane Proteins Human genes 0.000 claims description 12
- 230000009145 protein modification Effects 0.000 claims description 11
- 108010017384 Blood Proteins Proteins 0.000 claims description 10
- 102000004506 Blood Proteins Human genes 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 5
- 230000000857 drug effect Effects 0.000 claims description 4
- 239000000107 tumor biomarker Substances 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940125648 antineoplastic drug candidate Drugs 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 39
- 201000010099 disease Diseases 0.000 abstract description 34
- 239000000203 mixture Substances 0.000 abstract description 28
- 230000007246 mechanism Effects 0.000 abstract description 16
- 238000013461 design Methods 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 230000002062 proliferating effect Effects 0.000 abstract description 6
- 238000011156 evaluation Methods 0.000 abstract description 5
- 238000009510 drug design Methods 0.000 abstract description 4
- 230000002974 pharmacogenomic effect Effects 0.000 abstract description 3
- 238000004819 disease profiling Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 155
- 210000004027 cell Anatomy 0.000 description 98
- 108020004999 messenger RNA Proteins 0.000 description 65
- 150000007523 nucleic acids Chemical class 0.000 description 51
- 239000000523 sample Substances 0.000 description 50
- 102000039446 nucleic acids Human genes 0.000 description 49
- 108020004707 nucleic acids Proteins 0.000 description 49
- 238000012360 testing method Methods 0.000 description 46
- 108020004635 Complementary DNA Proteins 0.000 description 40
- 108020004705 Codon Proteins 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 37
- 150000001413 amino acids Chemical class 0.000 description 36
- 238000010804 cDNA synthesis Methods 0.000 description 36
- 239000002299 complementary DNA Substances 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 24
- 239000003446 ligand Substances 0.000 description 24
- 230000008569 process Effects 0.000 description 24
- 238000009396 hybridization Methods 0.000 description 21
- 238000012163 sequencing technique Methods 0.000 description 21
- 230000003321 amplification Effects 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 230000037429 base substitution Effects 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 230000008685 targeting Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000010357 RNA editing Methods 0.000 description 6
- 230000026279 RNA modification Effects 0.000 description 6
- 230000003915 cell function Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 5
- 108091027974 Mature messenger RNA Proteins 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229960004927 neomycin Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 230000009268 pathologic speech processing Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- -1 3' polyadenylation Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Chemical group 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100109141 Mesocricetus auratus APOAI gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000004474 valine Chemical group 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100030942 Apolipoprotein A-II Human genes 0.000 description 1
- 102100030970 Apolipoprotein C-III Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100025579 Calmodulin-2 Human genes 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 108091028709 DNA adenine Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000793406 Homo sapiens Apolipoprotein A-II Proteins 0.000 description 1
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 description 1
- 101000984150 Homo sapiens Calmodulin-2 Proteins 0.000 description 1
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 description 1
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 description 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
- 101100537779 Homo sapiens TPM2 gene Proteins 0.000 description 1
- 101000658157 Homo sapiens Thymosin beta-4 Proteins 0.000 description 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 101000803403 Homo sapiens Vimentin Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Chemical group 0.000 description 1
- 102100035000 Thymosin beta-4 Human genes 0.000 description 1
- 101150013734 Tmsb4x gene Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100036471 Tropomyosin beta chain Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000005101 luminescent paint Substances 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Glass Compositions (AREA)
- Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291176A EP1887088A1 (en) | 2006-07-20 | 2006-07-20 | Transcription infidelity, detection and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201112295Y true TR201112295Y (tr) | 2018-08-27 |
Family
ID=37496681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2011/12295U TR201112295Y (tr) | 2006-07-20 | 2007-07-20 | transkripsiyon infidelitesi, tespit edilmesi ve kullanımları |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8288091B2 (enExample) |
| EP (3) | EP1887088A1 (enExample) |
| JP (1) | JP5298013B2 (enExample) |
| KR (1) | KR101502179B1 (enExample) |
| AT (1) | ATE524565T1 (enExample) |
| AU (1) | AU2007275068B2 (enExample) |
| BR (1) | BRPI0714563B8 (enExample) |
| CA (1) | CA2658305C (enExample) |
| CY (2) | CY1112125T1 (enExample) |
| DK (2) | DK2046986T3 (enExample) |
| ES (2) | ES2373428T3 (enExample) |
| HU (1) | HUE028135T2 (enExample) |
| IL (1) | IL196600A0 (enExample) |
| PL (2) | PL2046986T3 (enExample) |
| PT (2) | PT2046986E (enExample) |
| SI (2) | SI2468885T1 (enExample) |
| TR (1) | TR201112295Y (enExample) |
| WO (1) | WO2008009751A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2071334A1 (en) * | 2007-12-14 | 2009-06-17 | Transmedi SA | Compositions and methods of detecting TIABS |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| EP2995688A1 (en) | 2014-09-12 | 2016-03-16 | Genclis | Methods of prognosing and treating triple negative breast cancer |
| WO2017100789A1 (en) * | 2015-12-11 | 2017-06-15 | Expression Pathology, Inc. | Srm/mrm assays |
| LT3430390T (lt) | 2016-03-18 | 2022-11-25 | Genclis | Molekulinė alergijos kilmė |
| WO2018187216A1 (en) * | 2017-04-03 | 2018-10-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Expression cassettes and methods for detecting transcription errors |
| EP3700856A4 (en) | 2017-10-26 | 2021-12-15 | Ultima Genomics, Inc. | METHODS AND SYSTEMS FOR SEQUENCE CALL |
| CN113795887A (zh) | 2019-03-10 | 2021-12-14 | 阿尔缇玛基因组学公司 | 用于序列判定的方法和系统 |
| WO2021030271A2 (en) | 2019-08-09 | 2021-02-18 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
| KR102334576B1 (ko) * | 2019-08-12 | 2021-12-07 | 한국생명공학연구원 | 융합 단백질 및 이를 포함하는 바이오 이미징용 조성물 |
| EP4211268A4 (en) * | 2020-09-10 | 2024-09-18 | Ultima Genomics, Inc. | SEQUENCE AND VARIANT CALLING METHODS AND SYSTEMS |
| WO2022108309A1 (ko) * | 2020-11-18 | 2022-05-27 | 한양대학교 에리카산학협력단 | 인산화된 비멘틴의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법 |
| EP4162948A1 (en) | 2021-10-05 | 2023-04-12 | Genclis | Transcription infidelity derived chimeric immunogens and uses thereof |
| WO2023104904A2 (en) | 2021-12-08 | 2023-06-15 | Genclis | The sars-cov-2 and variants use two independent cell receptors to replicate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4979330A (en) | 1989-10-10 | 1990-12-25 | Rorant Julius W | Suction insect trap device |
| US6120992A (en) | 1993-11-04 | 2000-09-19 | Valigene Corporation | Use of immobilized mismatch binding protein for detection of mutations and polymorphisms, and allele identification in a diseased human |
| WO2001040804A2 (en) * | 1999-12-03 | 2001-06-07 | Koninklijke Nederlandse Akademie Van Wetenschappen | Clearance of aberrant protein in correlation with disease |
| US20020132259A1 (en) | 2001-02-21 | 2002-09-19 | Wagner Robert E. | Mutation detection using MutS and RecA |
| WO2006053061A2 (en) * | 2004-11-10 | 2006-05-18 | Kansas State University Research Foundation | Porcine reproductive and respiratory syndrome virus receptor components and uses thereof |
-
2006
- 2006-07-20 EP EP06291176A patent/EP1887088A1/en not_active Withdrawn
-
2007
- 2007-07-20 EP EP11173357.2A patent/EP2468885B1/en not_active Not-in-force
- 2007-07-20 TR TR2011/12295U patent/TR201112295Y/tr unknown
- 2007-07-20 HU HUE11173357A patent/HUE028135T2/en unknown
- 2007-07-20 KR KR1020097003423A patent/KR101502179B1/ko not_active Expired - Fee Related
- 2007-07-20 JP JP2009519996A patent/JP5298013B2/ja not_active Expired - Fee Related
- 2007-07-20 PL PL07787788T patent/PL2046986T3/pl unknown
- 2007-07-20 PL PL11173357T patent/PL2468885T3/pl unknown
- 2007-07-20 US US12/374,431 patent/US8288091B2/en not_active Expired - Fee Related
- 2007-07-20 ES ES07787788T patent/ES2373428T3/es active Active
- 2007-07-20 DK DK07787788.4T patent/DK2046986T3/da active
- 2007-07-20 SI SI200731705T patent/SI2468885T1/sl unknown
- 2007-07-20 EP EP07787788A patent/EP2046986B1/en active Active
- 2007-07-20 PT PT07787788T patent/PT2046986E/pt unknown
- 2007-07-20 AU AU2007275068A patent/AU2007275068B2/en not_active Ceased
- 2007-07-20 PT PT111733572T patent/PT2468885E/pt unknown
- 2007-07-20 BR BRPI0714563A patent/BRPI0714563B8/pt not_active IP Right Cessation
- 2007-07-20 SI SI200730791T patent/SI2046986T1/sl unknown
- 2007-07-20 ES ES11173357.2T patent/ES2553435T3/es active Active
- 2007-07-20 DK DK11173357.2T patent/DK2468885T3/da active
- 2007-07-20 CA CA2658305A patent/CA2658305C/en active Active
- 2007-07-20 WO PCT/EP2007/057541 patent/WO2008009751A2/en not_active Ceased
- 2007-07-20 AT AT07787788T patent/ATE524565T1/de active
-
2009
- 2009-01-19 IL IL196600A patent/IL196600A0/en active IP Right Grant
-
2011
- 2011-12-09 CY CY20111101225T patent/CY1112125T1/el unknown
-
2015
- 2015-11-17 CY CY20151101031T patent/CY1116939T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201112295Y (tr) | transkripsiyon infidelitesi, tespit edilmesi ve kullanımları | |
| Knupp et al. | NOVA2 regulates neural circRNA biogenesis | |
| Liu et al. | circFL-seq reveals full-length circular RNAs with rolling circular reverse transcription and nanopore sequencing | |
| EP2080812A1 (en) | Compositions and methods of detecting post-stop peptides | |
| CN103134938B (zh) | 适体在蛋白质组学中的用途 | |
| KR20130100051A (ko) | 공간적으로 엔코딩된 생물학적 검정 | |
| CN102105585A (zh) | 对dna进行定量或检测的方法 | |
| CN112442530B (zh) | 检测cah相关真假基因的方法 | |
| WO2003107249A1 (en) | Method for predicting a drug transport capability by abcg2 polymorphisms | |
| Sirica et al. | Advancing Non-Invasive Prenatal Screening: A Targeted 1069-Gene Panel for Comprehensive Detection of Monogenic Disorders and Copy Number Variations | |
| Qi et al. | Cellular indexing of transcriptomes and epitopes by sequencing unveils coordinated RNA and protein landscape in ovary at single-cell resolution | |
| Stingl | Separate & analyze: Improved mass spectrometry-based clinical proteomics by fractionation | |
| Chisti et al. | " GENETIC BASIS OF RARE DISEASES: ADVANCES IN DIAGNOSIS AND THERAPEUTIC APPROACHES | |
| KIM et al. | Review Recent methodological advances towards single-cell proteomics | |
| CN119242803A (zh) | 一种检测白血病患者dna结构变异区域的方法及其应用 | |
| Alvikas et al. | Modern Techniques for DNA, RNA, and Protein Assessment | |
| HK1128937B (en) | Transcription infidelity, detection and uses thereof | |
| SYNtheSiS | article watch | |
| Clive | article watch | |
| AU2007240202A1 (en) | Novel compositions and methods for cancer |